<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01981252</url>
  </required_header>
  <id_info>
    <org_study_id>ULT-137</org_study_id>
    <nct_id>NCT01981252</nct_id>
  </id_info>
  <brief_title>Peri-orbital and Peri-oral Wrinkle Reduction Trial</brief_title>
  <official_title>Evaluation of the Safety and Efficacy of the Ulthera® System for Wrinkle Reduction in the Peri-orbital and Peri-oral Regions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ulthera, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz North America, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is prospective, multi-center, single-blinded, non-randomized clinical trial. Enrolled&#xD;
      subjects will receive two Ulthera® treatments on the peri-orbital and peri-oral regions, each&#xD;
      treatment provided 30 days apart. Follow-up visits will occur at 90 and 180 days following&#xD;
      treatment. Study images will be obtained pre-treatment, immediately post-treatment, and at&#xD;
      each follow-up visit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of efficacy.&#xD;
  </why_stopped>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with reduction in peri-orbital and/or peri-oral wrinkles at 90 days post-treatment #2.</measure>
    <time_frame>Participants will be followed to 90 days post-treatment #2</time_frame>
    <description>Assessment of improvement, in a blinded fashion, using the Fitzpatrick Wrinkle Scale at 90 days post-treatment #2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with reduction in peri-orbital and/or peri-oral wrinkles at 180 days Post Treatment #2.</measure>
    <time_frame>Participants will be followed to 180 days post-treatment #2</time_frame>
    <description>Assessment of improvement, in a blinded fashion, using the Fitzpatrick Wrinkle Scale at 180 days post-treatment #2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a reduction in peri-orbital and/or peri-oral wrinkle depth at 90 days post treatment #2.</measure>
    <time_frame>Participants will be followed to 90 days post-treatment #2</time_frame>
    <description>Quantitative wrinkle depth measurements will be performed using a 3-D imaging system at 90 days post-treatment #2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a reduction in peri-orbital and/or peri-oral wrinkle depth at 180 days Post Treatment #2.</measure>
    <time_frame>Participants will be followed to 180 days post-treatment #2</time_frame>
    <description>Quantitative wrinkle depth measurements will be performed using a 3-D imaging system at 180 days post-treatment #2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Aesthetic Improvement</measure>
    <time_frame>Participants will be followed to 90 days post-treatment #2</time_frame>
    <description>Overall aesthetic improvement at 90 days post treatment #2 compared to baseline will be assessed using the Global Aesthetic Improvement Scale (GAIS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Aesthetic Improvement</measure>
    <time_frame>Participants will be followed to 180 days post-treatment #2</time_frame>
    <description>Overall aesthetic improvement at 180 days post treatment #2 compared to baseline will be assessed using the Global Aesthetic Improvement Scale (GAIS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction</measure>
    <time_frame>Participants will be followed to 90 days post-treatment #2</time_frame>
    <description>Subject satisfaction will be measured at using a Patient Satisfaction Questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Peri-orbital Wrinkles</condition>
  <condition>Peri-oral Wrinkles</condition>
  <arm_group>
    <arm_group_label>Ulthera® System Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ulthera® System treatment of the peri-orbital and peri-oral regions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ulthera® System Treatment</intervention_name>
    <description>Focused ultrasound energy delivered below the surface of the skin</description>
    <arm_group_label>Ulthera® System Treatment</arm_group_label>
    <other_name>Ultherapy®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, age 30 to 75 years.&#xD;
&#xD;
          -  Subject in good health.&#xD;
&#xD;
          -  BMI&lt;25&#xD;
&#xD;
          -  Fitzpatrick wrinkle score of 3-7 in the peri-orbital and peri-oral areas.&#xD;
&#xD;
          -  Moderate skin laxity in the peri-orbital area contributing to rhytids as assessed by&#xD;
             the investigator.&#xD;
&#xD;
          -  Understands and accepts the obligation not to undergo any other procedures, including&#xD;
             neurotoxin and filler treatments, on the face through the follow-up period.&#xD;
&#xD;
          -  Willingness to refrain from use of aspirin, Ibuprofen, Naproxen or any other NSAID,&#xD;
             and Vitamin E in the 2 weeks prior to each study treatment.&#xD;
&#xD;
          -  Willingness and ability to continue with their current daily skin care routine, with&#xD;
             the exception of any use of products containing glycolic acid, for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Willingness and ability to comply with protocol requirements, including returning for&#xD;
             follow-up visits and abstaining from exclusionary procedures for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Subjects of childbearing potential must have a negative urine pregnancy test result&#xD;
             and must not be lactating at the Screening Visit and be willing and able to use an&#xD;
             acceptable method of birth control during the study.&#xD;
&#xD;
          -  Absence of physical or psychological conditions unacceptable to the investigator.&#xD;
&#xD;
          -  Willingness and ability to provide written consent for study-required photography and&#xD;
             adherence to photography procedures (i.e., removal of jewelry and makeup).&#xD;
&#xD;
          -  Willingness and ability to provide written informed consent and HIPAA authorization&#xD;
             prior to performance of any study-related procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of an active systemic or local skin disease that may affect wound healing.&#xD;
&#xD;
          -  BMI equal to or greater than 25&#xD;
&#xD;
          -  Severe solar elastosis.&#xD;
&#xD;
          -  Excessive subcutaneous fat in the area(s) to be treated.&#xD;
&#xD;
          -  Mild or severe skin laxity on the area(s) to be treated.&#xD;
&#xD;
          -  Significant scarring in the area(s) to be treated.&#xD;
&#xD;
          -  Open wounds or lesions in the area(s) to be treated.&#xD;
&#xD;
          -  Severe or cystic acne on the area(s) to be treated.&#xD;
&#xD;
          -  Active implantables (e.g., pacemakers or defibrillators) or metallic implants in the&#xD;
             treatment area.&#xD;
&#xD;
          -  Inability to understand the protocol or to give informed consent.&#xD;
&#xD;
          -  Microdermabrasion, or prescription level glycolic acid treatment to the treatment&#xD;
             area(s) within 4 weeks prior to study participation or during the study.&#xD;
&#xD;
          -  Marked asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, or thick&#xD;
             sebaceous skin in the area(s) to be treated.&#xD;
&#xD;
          -  History of chronic drug or alcohol abuse.&#xD;
&#xD;
          -  History of autoimmune disease.&#xD;
&#xD;
          -  History of Bell's Palsy or epilepsy.&#xD;
&#xD;
          -  History of diabetes.&#xD;
&#xD;
          -  Has a known allergy, or a known history of sensitivity, to lidocaine, tetracaine,&#xD;
             para-aminobenzoic acid (PABA).&#xD;
&#xD;
          -  Concomitant therapy that, in the investigator's opinion, would interfere with the&#xD;
             evaluation of the safety or efficacy of the study device.&#xD;
&#xD;
          -  Subjects who anticipate the need for surgery or overnight hospitalization during the&#xD;
             study.&#xD;
&#xD;
          -  Subjects who, in the investigator's opinion, have a history of poor cooperation,&#xD;
             noncompliance with medical treatment, or unreliability.&#xD;
&#xD;
          -  Concurrent enrollment in any study involving the use of investigational devices or&#xD;
             drugs.&#xD;
&#xD;
          -  Current smoker or history of smoking in the last five years.&#xD;
&#xD;
          -  History of the following cosmetic treatments in the area(s) to be treated:&#xD;
&#xD;
               1. Skin tightening procedure within the past year;&#xD;
&#xD;
               2. Injectable fillers of any type within the past 12 or 24 months, depending on&#xD;
                  type;&#xD;
&#xD;
               3. Neurotoxins within the past six months;&#xD;
&#xD;
               4. Ablative resurfacing laser treatment;&#xD;
&#xD;
               5. Nonablative, rejuvenative laser or light treatment within the past six months;&#xD;
&#xD;
               6. Surgical dermabrasion or deep facial peels;&#xD;
&#xD;
               7. Facelift, blepharoplasty, or browlift within the past 2 years; or&#xD;
&#xD;
               8. Any history of contour threads.&#xD;
&#xD;
          -  History of using the following prescription medications:&#xD;
&#xD;
               1. Accutane or other systemic retinoids within the past six months;&#xD;
&#xD;
               2. Topical Retinoids within the past four weeks;&#xD;
&#xD;
               3. Antiplatelet agents/Anticoagulants;&#xD;
&#xD;
               4. Psychiatric drugs that in the investigators opinion would impair the subject from&#xD;
                  understanding the protocol requirements or understanding and signing the informed&#xD;
                  consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Biesman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nashville Centre for Laser and Facial Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Advanced Facial Plastic Surgery</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aesthetic Plastic Surgical Institute</name>
      <address>
        <city>Laguna Beach</city>
        <state>California</state>
        <zip>92651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>About Skin Dermatology and DermSurgery, PC</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Institute</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Centre for Laser and Facial Surgery</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>November 4, 2013</study_first_submitted>
  <study_first_submitted_qc>November 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2013</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulthera® System</keyword>
  <keyword>Ultherapy™ Treatment</keyword>
  <keyword>Ulthera, Inc.</keyword>
  <keyword>Micro-focused Ultrasound with Visualization (MFU-V)</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

